Philip Friedlander, MD, PhD
img_Philip Friedlander
ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
ASSISTANT PROFESSOR | Dermatology
Are you a patient?
Specialties
Internal Medicine, Cancer (Oncology)

MD, Columbia University College of Physicians & Surgeons

Internship, Internal Medicine, Columbia Presbyterian Medical Center

Residency, Internal Medicine, Columbia Presbyterian Medical Center

Fellowship, Medical Oncology, Memorial Sloan-Kettering Cancer Center

Certifications

American Board of Internal Medicine
Publications

Selected Publications

Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. Jason A. Chesney, Igor Puzanov, Frances A. Collichio, Parminder Singh, Mohammed M. Milhem, John Glaspy, Omid Hamid, Merrick Ross, Philip Friedlander, Claus Garbe, Theodore Logan, Axel Hauschild, Celeste Lebbé, Harshada Joshi, Wendy Snyder, Janice M. Mehnert. Journal for ImmunoTherapy of Cancer

Preclinical Activity of 4-Demethyl-4-cholesteryloxycarbonylpenclomedine in Melanoma. Philip Friedlander, Lee Roy Morgan, Edmund N. Benes, Andrew H. Rodgers, Branko Jursic. Anticancer Research

Targeted therapy for cutaneous malignancies. Aleksandar Sekulic, Michael R. Migden, Anthony E. Oro, Luc Dirix, Karl D. Lewis, John D. Hainsworth, James A. Solomon, Simon Yoo, Sarah T. Arron, Philip A. Friedlander, Ellen Marmur, Charles M. Rudin, Anne Lynn S. Chang, Jennifer A. Low, Howard M. Mackey, Robert L. Yauch, Richard A. Graham, Josina C. Reddy, Axel Hauschild, Eve Maubec, Peter Petrow, Isabelle Scheer-Senyarich, Pierre Duvillard, Ludovic Lacroix, Julien Gelly, Agnès Certain, Xavier Duval, Béatrice Crickx, Valérie Buffard, Nicole Basset-Seguin, Pierre Saez, Anne Duval-Modeste, Adamski Bénédicte, Mansard Henri, Grange Sandrine, Dompmartin Florent, Faivre Anne, Mentré Sandrine, Avril France, Marie Françoise, G. V. Long, A. Hauschild, M. Santinami, V. Atkinson, M. Mandal, V. Chiarion-Sileni, J. Larkin, M. Nyakas, C. Dutriaux, A. Haydon, C. Robert, L. Mortier, J. Schachter, D. Schadendorf, T. Lesimple, R. Plummer, R. Ji, P. Zhang, B. Mookerjee, J. Legos, R. Kefford, R. Dummer, J. M. Kirkwood.

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Friedlander during 2023 and/or 2024. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting or Other Professional Services: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Miscellaneous MedicoLegal
  • Castle Biosciences Inc.
  • DBV Technologies
  • Guidepoint Global

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Iovance Biotherapeautics
  • GE Healthcare
  • Gilead Sciences

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.